Achieving cost-neutrality with long-acting reversible contraceptive methods-Reference-Cited by-同舟云学术

Achieving cost-neutrality with long-acting reversible contraceptive methods

Published:2015-01 Issue:1 Volume:91 Page:49-56
ISSN:0010-7824
Container-title:Contraception
language:en
Short-container-title:Contraception

Author:

Trussell James,Hassan Fareen,Lowin Julia,Law Amy,Filonenko Anna

Funder

Bayer Healthcare Pharmaceuticals Inc.

Eunice Kennedy Shriver National Institute of Child Health and Human Development grant for Infrastructure for Population Research at Princeton University

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference21 articles.

1. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception;Trussell;Contraception,2012

2. Public funding for family planning, sterilization and abortion services, FY 1980–2010;Sonfield,2012

3. Unintended pregnancy and taxpayer spending;Monea;Perspect Sex Reprod Health,2011

4. US agencies providing publicly funded contraceptive services in 1999;Finer;Perspect Sex Reprod Health,2002

5. Contraceptive discontinuation attributed to method dissatisfaction in the United States;Moreau;Contraception,2007

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities in patients with adult congenital heart disease, a narrative review;Frontiers in Cardiovascular Medicine;2024-05-30

2. Review of publicly available state reimbursement policies for removal and reinsertion of Long-Acting Reversible Contraception;2024-05-12

3. Where Microsurgical Tubal Reanastomosis Stands in the In vitro Fertilization Era;Gynecology and Minimally Invasive Therapy;2024-04

4. Early removal of the etonogestrel contraceptive implant in Spanish women: a prospective cohort study;Frontiers in Medicine;2024-01-23

5. Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims;Journal of Managed Care & Specialty Pharmacy;2023-12